Fibroblast growth factor 20 (FGF20)

Fibroblast growth factor 20 (FGF20) is a secreted heparin-binding growth factor and a member of the FGF family, specifically the FGF-9 subfamily, consisting of a 211 amino acid polypeptide without a classic signal peptide[2]. It is expressed in several cell types, including dopaminergic neurons, fibroblasts, keratinocytes, and breast epithelium, and has high sequence identity across species[2]. FGF20 binds to multiple fibroblast growth factor receptor isoforms (FGFR1c, FGFR2c, FGFR3b, FGFR3c, FGFR4), mediating diverse biological effects including cell proliferation, cell differentiation (notably into dopaminergic neurons), and tissue regeneration; its signaling involves the RAS/MAPK, PI3K/AKT, and PLCγ pathways[1][2][3]. Genetic variants in FGF20 have been linked to increased risk for Parkinson’s disease, and its expression is regulated by the Wnt/β-catenin pathway, implicating it in tumorigenesis[2]. While FGF20 and its signaling partners are being investigated as therapeutic targets for neurodegenerative diseases and tissue regeneration, no direct FGF20-targeting drugs are currently in clinical use, and safety concerns include a potential for abnormal tissue growth or neoplasia with unregulated activity[1][2].

Other names

FGF20FGF-20RHDA2fibroblast growth factor 20

Activation or inhibition of FGF20 modulates FGFR (fibroblast growth factor receptor) signaling, affecting downstream pathways such as RAS/MAPK, PI3K/AKT, and PLCγ, influencing cell proliferation and differentiation[1][2].